Austin, TX 12/5/2007 11:09:30 PM
Speak with other shareholders about: (Nasdaq: FLOW), (Nasdaq: SNTA), (Nasdaq: OCLS)
Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the Chat Live button at the top.
----------------------------------------------------------
Chat real-time with other investors about this FLOW news release,
by clicking this link: http://www.stockwire.com/FLOW
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=FLOW
Flow International Corporation (Nasdaq: FLOW) Closed at $7.36. Today announced that it has signed an exclusive option agreement to negotiate the acquisition of OMAX Corporation.
OMAX is a Kent, WA-based privately held provider of precision-engineered, computer-controlled, abrasive waterjet systems. Under the terms of the agreement, Flow and OMAX will work to negotiate a definitive agreement for Flow to acquire OMAX. Upon closing, Flow would pay approximately $109 million in cash and stock (including the amounts paid for the option agreement) with the potential for a contingent earn-out in two years of up to $26 million in either stock or cash at Flow's option. A transaction to combine the two companies is subject to completion of all due diligence, execution of a definitive agreement, Hart-Scott-Rodino anti-trust clearance, and customary closing conditions.
----------------------------------------------------------
Chat real-time with other investors about this SNTA news release,
by clicking this link: http://www.stockwire.com/SNTA
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=SNTA
Synta Pharmaceuticals (Nasdaq: SNTA) Closed at $7.34. Today announced that it has received an upfront non-refundable cash payment of $80 million from GlaxoSmithKline (GSK) following expiration of the waiting period imposed by the Federal Trade Commission (FTC) under the Hart Scott Rodino Antitrust Improvements Act for their collaboration agreement for the joint development and commercialization of elesclomol entered into on October 8, 2007. Elesclomol is a first-in-class, small-molecule, oxidative stress inducer that is currently in a global, pivotal Phase 3 trial in metastatic melanoma - the SYMMETRY trial.
----------------------------------------------------------
Chat real-time with other investors about this OCLS news release,
by clicking this link: http://www.stockwire.com/OCLS
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=OCLS
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) Closed at $4.79. Today announced completion of enrollment of its Phase II clinical trial of Microcyn Technology. The company has enrolled and randomized 67 patients in its open-label Phase II clinical trial evaluating its Microcyn Technology in the treatment of mildly infected diabetic foot ulcers. The study, which is being conducted at 15 U.S. sites, is specifically designed to demonstrate that topical Microcyn has sufficiently similar cure and improvement rates to oral levofloxacin. This would provide the rationale for larger Phase III trials designed to demonstrate statistically significant safety and efficacy, fundamental in securing NDA marketing approval. Also being examined are a number of other trial parameters for consideration in the design of the larger Phase III trials that will be required for FDA approval. The company expects to provide preliminary top line results in the first calendar quarter of 2008.
--------------------------------------------------
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and/or the National Association of Securities Dealers (NASDAQ) at www.NASDAQ.com. The NASDAQ has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We often receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares into the open market.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
